NCT06540963 2026-03-02Tipifarnib and Naxitamab for Relapsed/Refractory NeuroblastomaMilton S. Hershey Medical CenterPhase 2 Recruiting98 enrolled
NCT03363373 2026-02-19Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone MarrowY-mAbs TherapeuticsPhase 2 Recruiting122 enrolled 2 FDA